AI Insight
A phase 3 clinical trial (DESTINY-Lung04) demonstrated that first-line treatment with trastuzumab deruxtecan significantly improved progression-free survival compared to pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer. The results were presented at the 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
Why it matters
This finding could establish a new standard first-line treatment option for patients with HER2-mutant NSCLC, a specific subset of lung cancer patients who may benefit from targeted therapy rather than standard immunotherapy-chemotherapy combinations. The results suggest that targeted approaches based on specific genetic mutations can improve outcomes in lung cancer treatment.
Understand the Science
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).